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Investigation of protein-protein interactions (PPIs)
andprotein phosphorylation in clinical tissue samples
can offer valuable information about the activa-
tion status and function of proteins involved in dis-
ease progression. However, existing antibody-based
methods for phosphorylation detection have been
found to lack specificity, and methods developed for
examining PPIs in vitro cannot be easily adapted for
tissues samples. In this study, we eliminated some
of these limitations by developing a specific immu-
nohistochemical staining method that uses ‘‘dual
binders’’ (DBs), which are bispecific detection agents
consisting of two Fab fragment molecules joined by
a flexible linker, to detect PPIs and protein phosphor-
ylation. We engineered DBs by selecting Fab frag-
ments with fast off-rate kinetics, which allowed us to
demonstrate that stable target binding was achieved
only upon simultaneous, cooperative binding to
both epitopes. We show that DBs specifically detect
the activated HER2/HER3 complex in formalin-fixed,
paraffin-embedded cancer cells and exhibit superior
detection specificity for phospho-HER3 compared
to the corresponding monoclonal antibody. Overall,
the performance of DBs makes them attractive tools
for future development for clinical applications.
INTRODUCTION
Over the past few decades, research in various fields of biology
have provided us with a great wealth of information about func-
tions, interactions, and signaling pathways of human proteins
and their possible relevance in health and disease.
Some of the challenges of the future will be to interpret and
validate these findings in human physiology and pathology and
to demonstrate the relevance of in vitro studies in clinicalChemistry & Biology 21, 3settings, especially in oncology. This is often referred to as trans-
lational research and from bench to bedside (Wagner and Srivas-
tava, 2012; Curry, 2008). A watershed in translational science
occurred in 1998, when the U.S. Food and Drug Administration
approved trastuzumab and a companion diagnostic immunohis-
tochemistry (IHC) assay used to detect the human epidermal
growth factor receptor 2 (HER2). The assay is performed on
formalin-fixed, paraffin-embedded (FFPE) tissue tumor samples,
and a positive result indicates that a patient should be treated
with trastuzumab (Cobleigh et al., 1999; Slamon et al., 2001).
The assay served as a key milestone in the fields of biomarker
research and molecular pathology, as it allowed the correlation
of scientific knowledge about HER2 expression in cancer to an
improvement in breast cancer therapy (McCourt et al., 2013).
As next steps, our understanding of tumor biology would be
even enhanced if it were possible to look beyond the simple
expression of proteins and to be able to investigate protein-pro-
tein interactions (PPIs) and protein phosphorylation. As a conse-
quence, one would obtain valuable information about the activa-
tion status and function of proteins from clinical tissue samples.
Unfortunately, the detection of protein phosphorylation using
monoclonal antibodies in IHC suffers from unreliable specificity
(Mandell, 2003, 2008; Waraich et al., 2008). Further, although
formalin fixation and paraffin embedding are still the gold stan-
dard for tissue preservation, manymethods used to characterize
PPIs, including coimmunoprecipitation, fluorescence resonance
energy transfer, and mass spectrometry studies, are difficult
to apply to FFPE tissue material. Several new methods are
emerging to improve the detection of PPIs and posttranslational
modifications (PTMs) in FFPE tissue. Most of them are based on
proximity ligation assays (So¨derberg et al., 2006; Fredriksson
et al., 2002). In addition, the fluorescent VeraTag reporter
technology (Monogram Biosciences/LabCorp) shows promise
for detecting PPIs and PTMs, but it comes with the disadvantage
of complete loss of information about tissue morphology and
heterogeneous signaling patterns (Mukherjee et al., 2011;
Fazio-Eli et al., 2011; Shi et al., 2009).
In this report, we introduce an improved IHC technology for the
detection of PPIs and protein phosphorylation using bispecific
molecules that we call dual binders (DBs).57–368, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 357
Figure 1. IHC Detection of PPI and Protein Phosphorylation Using DBs
PPI as a target specificity and specific protein phosphorylation are detected if a DB can interact with both epitopes simultaneously to form a stable
complex
(A) The complex of the target with only one arm of the DB dissociates very fast, and the DB is washed off immediately upon automated IHC staining.
(B) Two Fab fragments are linked by G4S amino acid motives and a HA-tag in a
pepDB.
(C) Two Fab fragments are linked by ssDNA hybridization by a digoxigenin(dig)-labeled HEG spacer in a DNADB.
See also Figure S1.
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‘‘Dual Binders’’ Boost In Situ Detection SpecificityOver the past few years, a variety of new antibody formats
have emerged (Byrne et al., 2013; Kontermann, 2012; Chames
and Baty, 2009). Most notably, bispecific antibodies have been
investigated in a therapeutic setup (Schaefer et al., 2011) and
so-called zybodies were developed that provide the basis for
therapeutic agents comprising an antibody scaffold (LaFleur
et al., 2013). By grafting two or even more distinct specificities
in a single binder molecule, different antigens can be targeted
simultaneously with higher efficacy. Furthermore, DNA-antibody
conjugates have recently been described. Kazane et al. showed
the potential of antibody multimers through peptide nucleic acid
conjugation that recruit cytotoxic T lymphocytes to HER2- and
CD20-positive cancer cells (Kazane et al., 2013). In another
study, Kazane et al. also demonstrated the potential of DNA-
antibody conjugates for immuno-PCR applications, e.g., for
the highly sensitive immuno-PCR assay to detect even rare
HER2-positive cells in a complex cellular environment (Kazane
et al., 2012).
Complementarily to the previous work on bispecific formats,
we aimed to apply the recent advances in antibody technology
and their applications in diagnostic settings and developed
DBs for a tailored IHC application. DBs consist of two binding
elements, e.g., Fab fragments that are connected by flexible
linkers made of DNA, hexaethyleneglycol (HEG), or amino acids.
The Fab fragments are carefully selected from well-character-
ized antibodies with regard to their binding kinetics. Because
Fab fragments with moderate off-rate kinetics are chosen, DBs
are washed off if only one arm of the DB is bound to its epitope.
In contrast, simultaneous cooperative binding of both DB arms358 Chemistry & Biology 21, 357–368, March 20, 2014 ª2014 Elsevieprevents dissociation of the detection molecule and leads to
positive IHC staining. Further, the DBs increase the sensitivity
in the detection of protein phosphorylation by linking a Fab
fragment that is directed against the unspecific PTM to a Fab
fragment that is directed against a unique epitope of the target
protein (Figure 1).
In this paper, we demonstrate the power of DBs to detect PPIs
and protein phosphorylation in FFPE tissue by studying the acti-
vation of HER3, a member of the human epidermal growth factor
receptor family (HER), upon ligand stimulation. HER3 is known to
have no active kinase domain, which means it is not autophos-
phorylated in its inactive state (Jura et al., 2009). Only upon stim-
ulation with one of its ligands, HRG1 or HRG2, does the receptor
undergo a conformational change that allows heterodimerization
with other HER family members and subsequent transphos-
phorylation of HER3 (Cho and Leahy, 2002; Carraway et al.,
1994; Wallasch et al., 1995). The heterodimer HER2/HER3 has
been investigated extensively by coimmunoprecipitation studies
and is believed to be a highly regulated and active mitogenic
signaling complex. In addition, HER2/HER3 heterodimers are
thought to act as an escape mechanism for HER2-targeted
therapies in breast cancer (Citri et al., 2003; Tzahar et al.,
1996; Mukherjee et al., 2011; Sakai et al., 2007; Jain et al.,
2010; Agus et al., 2002).
In this paper, we also show that DB technology enables the
specific immunochemical detection of HER2/HER3 heterodime-
rization and HER3 phosphorylation upon heregulin (HRG) stim-
ulation in FFPE cancer cell lines MCF-7 and T47D. Further, we
demonstrate the increase in specificity of phosphorylatedr Ltd All rights reserved
Table 1. Antibodies Selected for DNADBHER2/HER3 Based on koff
Rates versus ‘‘Best’’ Antibodies of Same Immunization
Ab kon (1/ms) koff (1/s) KD (M)
AbHER3 1.2 3 10
5 9.4 3 10–4 7.7 3 10–9
AbHER3best 3.1 3 10
5 1.4 3 10–4 4.5 3 10–10
AbHER2 7.7 3 10
3 4.4 3 10–4 5.6 3 10–8
AbHER2best 1.9 3 10
5 3.2 3 10–5 1.6 3 10–10
See also Figure S5.
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‘‘Dual Binders’’ Boost In Situ Detection SpecificityHER3 (pHER3) detection using a peptide chip and FFPE xeno-
graft tissue.
RESULTS
Development of Dual Binders
In principle, several types of bispecific molecules, which have
already been used successfully in diagnostic and therapeutic
approaches, may be suitable as DBs (Byrne et al., 2013; Konter-
mann, 2012; Chames and Baty, 2009; Kazane et al., 2012, 2013;
Kim et al., 2012). In the present study, we used two different
bispecific molecule approaches, namely, DBs in which two
Fab fragments were connected by either a peptide linker (pepDB)
or a DNA/HEG-based linker (DNADB) (Figure 1). We assumed that
these DB formats were superior to conventional bispecific anti-
bodies, whose two Fab fragments are sterically more con-
strained due to the Fc region than in the flexible linker of the
DBs. Further, the modular setup of the DNA/HEG-based linker,
wherein two DNA-labeled Fab fragments hybridize the respec-
tive complementary DNA of the linker molecule, may allow for
an easy variation of the linker molecules and provide a potential
means by which to optimize the linker by screening a linker
library.
As outlined before, a critical step in the design of the DB is the
selection of Fab fragments with regard to their binding kinetics.
The optimal koff kinetics in our IHC setup have been determined
to be between 53 103 1/s and 13 104 1/s by surface plasmon
resonance (SPR) imaging. Usually, high-affinity monoclonal anti-
bodies have an approximately 10-fold lower koff rate (Table 1 and
Figure S5 available online). These off-rate kinetics were suffi-
ciently fast to ensure efficient removal upon washing, when
only one target epitope of the DB was available for ligation. At
the same time, the cooperative binding event, when both target
epitopes were available, was strong enough to withstand
washing, resulting in positive staining, as shown in Figures 2,
3, 4, and 5.
The pepDBs were expressed as recombinant proteins using
transient transfection of suspension-adapted HEK293 cells,
and subsequently purified by metal affinity chromatography,
through a polyhistidine Tag at the C terminus and size exclusion
chromatography. The linker peptide chain consisted of the hem-
agglutinin (HA)-Tag sequence flanked by flexible GGGGS mo-
tives (Figure 1). The HA-Tag was used to allow the detection of
pepDBs in IHC by a rabbit anti-HA antibody. Further, the two
Fab fragments of a pepDB were ideally derived from two different
species to avoid heavy chain/light chain mispairing (Lindhofer
et al., 1995). If Fab fragments were derived from the same spe-
cies, one of the Fab fragments was engineered to be expressedChemistry & Biology 21, 3as a human chimeric Fab. For the development of DNADBs, the
two Fab fragments were site-specifically conjugated with two
different single-stranded DNA (ssDNA) oligonucleotides. Site-
specific labeling occurred by using either a SNAP-Tag or a
sortase recognition Tag at the C terminus of the respective Fab
heavy chain (Pritz et al., 2007; Keppler et al., 2003). Two
ssDNA-labeled Fab fragments [Fab-oligonucleotide 1 (Fab-oligo
1) and Fab-oligo 2] were hybridizedwith ssDNA linker molecules,
which contained flanking nucleotide sequences complementary
to the ssDNA oligonucleotide sequences used for Fab labeling,
to form a DB. The nucleotide sequences of the linker were con-
nected by two motives of HEG to increase linker flexibility (Fig-
ure 1). Further, the linker was labeled with digoxigenin to enable
detection by an anti-digoxigenin antibody in IHC. The correct
assembly of a DNADB was monitored by analytical size exclusion
chromatography (SEC). For example, DNADBHER2/HER3, consist-
ing of the ssDNA linker (Sequence I in Experimental Procedures,
Oligonucleotide Synthesis), FabHER2 labeled with a 17-mer
(Sequence IV), and FabHER3 labeled with a 19-mer oligonucleo-
tide (Sequence V), eluted with a retention volume of 11.7 ml.
The unhybridized ssDNA linker (Sequence VIII), the single Fab-
oligo conjugates, and the complexes formed by an ssDNA linker
with one type of Fab-oligo (either FabHER2-oligo 1 or FabHER3-
oligo 2), eluted at larger retention volumes (Figure S1). Correct
assembly of a DNADB was corroborated by SDS-PAGE analysis
(Figure S1).
Detection of HER2/HER3 Heterodimers in Formalin-
Fixed and Paraffin-Embedded Cells
To demonstrate the power of using DBs in IHC to visualize
PPIs, we sought to detect the heterodimerization between
HER2 and HER3. The two receptors are known to dimerize
after stimulation of HER3 with HRG, and, upon dimerization,
HER3 is phosphorylated by HER2 (Citri et al., 2003). First, we
developed monoclonal antibodies in mice using hybridoma
technology to target the intracellular domains (ICDs) of HER2
and HER3. We then selected two antibodies that showed suit-
able off-rate kinetics in SPR (Table 1 and Figure S5). The anti-
bodies detected their targets specifically, as demonstrated by
IHC in which we used transfected HEK293 cells overexpressing
HER1, HER2, HER3, or HER4 (Figure S2). The amino acid se-
quences of the selected antibodies were determined by RT-
PCR sequencing with hybridoma mRNA as the template and
used to generate recombinant DBs. The two Fab fragments
(FabHER2 and FabHER3) were connected through a peptide linker
(pepDBHER2/HER3) or a DNA-based linker (
DNADBHER2/HER3). As
both antibodies were generated in mice, FabHER2 was designed
as a mouse/human chimeric Fab to avoid heavy-light chain
mispairing. The DBs were then characterized in IHC experi-
ments using the BenchMark XT staining platform (Ventana
Medical Systems) and the OptiView DAB IHC Detection Kit
(Ventana Medical Systems). We used MCF-7 and T47D cells
as model tumor cell lines. Both express HER2 and HER3 but
not HER1, and therefore no HER1/HER3 or HER1/HER2 oligo-
merization could interfere with the oligomerization between
HER2 and HER3. Ligand-treated and ligand-untreated cells
were fixed in formalin and embedded into paraffin. Further,
the stimulation of HER3 with HRG was validated by phospho-
HER3 IHC. The expression levels of HER2 and HER3 were57–368, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 359
Figure 2. Immunohistochemical Staining of MCF-7 Cells with DNADBHER2/HER3
(A–C) The fully formed DB stained HRG-treated MCF-7 cells (A), but it did not stain untreated cells (B) or cells treated with pertuzumab (C).
(D–G) HRG-treated cells were not stained using constructs of FabHER2-oligo 1 + linker (D) and FabHER3-oligo 2 + linker (E). Neither ssDNA linker alone (F) nor
FabHER2-oligo 1 together with FabHER3-oligo 2 in the absence of ssDNA linker (G) caused staining of HRG-stimulatedMCF-7 cells.
DNADBHER2/HER3 and its controls
were used at a concentration of 10 nM.
See also Figure S2.
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‘‘Dual Binders’’ Boost In Situ Detection Specificityassessed by IHC and did not change upon treatment with HRG
or pertuzumab, a therapeutic HER2-targeting antibody known
to inhibit HER2 heterodimerization.
IHC analysis with DNADBHER2/HER3 resulted in positive
membranous staining of MCF-7 cells that were treated with
HRG, but it did not stain untreated MCF-7 cells. Further,
DNADBHER2/HER3 did not stain MCF-7 cells that were treated
with HRG and pertuzumab. In addition, a monovalent binder
of FabHER2-oligo 1 hybridized to a ssDNA linker without
FabHER3-oligo 2 (and, respectively, a monovalent binder of
FabHER3-oligo 2 hybridized to an ssDNA linker without
FabHER2-oligo 1) did not stain HRG-treated MCF-7 cells. Neither
the ssDNA linker without Fab-oligo fragments nor two separate
monovalent binders, namely, FabHER2-oligo 1 and FabHER3-oligo
2 without a linker, caused positive staining of HRG-stimulated
MCF-7 cells (Figure 2).
In addition, pepDBHER2/HER3 also stainedMCF-7 cells that were
treated with HRG, but it did not stain untreated MCF-7 cells or
cells that were treated with HRG and pertuzumab. Positive stain-
ing of HRG-treated MCF-7 cells was inhibited by the addition of
HER-derived blocking peptides representing the FabHER2 and
FabHER3 recognition epitopes. The HER epitope peptides satu-
rated the HER2 or the HER3 binding site of pepDBHER2/HER3 and
consequently interfered with the binding of pepDBHER2/HER3 to
HRG-treated MCF-7 cells. A random peptide did not inhibit the
binding of pepDBHER2/HER3 to MCF-7 cells (Figure 3). Further,
pepDBHER2/HER3 also stained HRG-treated T47D cells, but it did
not stain untreated T47D cells. The positive staining of stimu-
lated T47D was also inhibited by the addition of the HER epitope
peptides (Figure S3). As a final control, starved or HRG-treated
MCF-7 cells were stained with either pepDBHER2/HER3 or the
respective (monospecific) immunoglobulin G (IgGs) against
HER2 or HER3 containing the Fab fragments of which the DB360 Chemistry & Biology 21, 357–368, March 20, 2014 ª2014 Elseviewas composed. Whereas the anti-HER2 and anti-HER3 IgGs
stained both starved and HRG-treated MCF-7 cells equally
well, the bispecific pepDBHER2/HER3 stained specifically the
HRG-stimulated MCF-7 cells (Figure S3).
Detection of Phosphorylated HER3 in Formalin-Fixed
and Paraffin-Embedded Cells
We also investigated the potential of phosphorylation state-spe-
cific DBs using phosphorylated HER3 as the target. One Fab
fragment (FabPHOS) of the DB targets a well-characterized
phosphoeptiope [HER3(1,283–1,295; pY1289)], the second
Fab fragment (FabSPEC) a HER3-specific non-phosphoepitope
[HER3(1,242–1,267)] of the ICD of the receptor. FabPHOS and
FabSPEC were derived from rabbit and mouse monoclonal
antibodies, respectively, and were selected based on moder-
ate off-rate kinetics in SPR analysis as described for the
DBHER2/HER3. First, a pHER3 DB with a HEG/DNA-based linker
(DNADBpHER3) was generated and characterized in IHC experi-
ments. We stained FFPE HEK293 cells that had been cotrans-
fected with an expression vector encoding the HER2 receptor
and a second expression vector encoding either Wild-Type
HER3 or a mutated version of HER3 [HER3(YICDF)] that lacked
all phosphorylation sites at its ICD. The DNADBpHER3 led to mem-
brane staining only of cells that expressed Wild-Type HER3 and
that had been treated with HRG. Untreated cells or HRG-treated
cells that expressed the mutant receptor did not stain. Neither
monovalent FabPHOS-oligo 1 nor monovalent FabSPEC-oligo 2
alone gave rise to positive staining, highlighting the requirement
for cooperative binding of both DB arms for a positive readout
(Figure 4). As a second variant, a DB containing a peptide linker
(pepDBpHER3) was characterized in IHC.
pepDBpHER3 led to similar
staining of the aforementioned transfected HEK293 cells as
DNADBpHER3. In this setting, similarly to the experiments withr Ltd All rights reserved
Figure 3. Immunohistochemical Staining of MCF-7 Cells with pepDBHER2/HER3
(A–C) The fully formed DB stained HRG-treated MCF-7 cells (A), but it did not stain untreated cells (B) or cells treated with pertuzumab (C).
(D and E) HRG-treated cells were not stained by the DB in the presence of the epitope peptides HER2(1,223–1,236) (D) or HER3(1,093–1,113) (E).
(F) The addition of a random peptide did not alter the staining.
pepDBHER2/HER3 was used at a concentration of 10 nM. See also Figure S3.
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‘‘Dual Binders’’ Boost In Situ Detection Specificitythe pepDBHER2/HER3, competitive peptides containing the epitope
recognition sequences of FabPHOS or FabSPEC efficiently pre-
vented positive staining (see Figure S4). pepDBpHER3 also stained
T47D cells (see Figure 5) and MCF-7 cells (data not shown), but
only cells that had been treated with HRG prior to fixation.
To assess a potential gain in target specificity, we compared
the pepDBpHER3 with the corresponding (bivalent) monoclonal
phosphorylation state-specific antibody (anti-pHER3 IgG)
that contained the phosphorylation state-specific paratope of
pepDBpHER3. First, we characterized binding specificity using a
peptide array chip onto which selected phosphoepitopes of
well-known signaling pathway proteins had been spotted using
the CelluSpotsTM (intavis Bioanalytical Instruments) technology.
The specificity evaluation experiments were conducted using
the Ventana Medical Systems BenchMark XT autostainer. Anti-
pHER3 IgG and pepDBpHER3 both detected the phosphorylated
HER3 peptide HER3(1,243–1,295; pY1289). In addition, only
the monoclonal anti-pHER3 IgG showed strong binding to
several other phosphoepitopes, most strongly to vascular endo-
thelial growth factor receptor 3 (VEGFR3)(1,330–1,344; pY1337),
fibroblast growth factor receptor 1 (FGFR1)(759–773; pY766),
FGFR2(762–776; pY769), FGFR3(753–767; pY760), and
FGFR4(747–761; pY754). Quantification of the obtained signals
revealed 5-fold to 20-fold decreased cross-reactivity of
pepDBpHER3 compared to anti-pHER3 IgG (Figure 6). Conse-
quently, pepDBpHER3 showed higher specificity for phosphory-
lated HER3 and less off-target binding than the monoclonal
anti-pHER3 antibody.
Next, both binders, pepDBpHER3 and monoclonal anti-pHER3
IgG, were compared regarding their in situ detection specificity.
In IHC experiments, H322M xenograft FFPE tissue sections
showed pronounced unspecific blood vessel staining, in addition
to the characteristic pHER3 membranous staining of prolifer-Chemistry & Biology 21, 3ating tumor cells, when anti-pHER3 IgG was used as the detec-
tion reagent. In contrast, unspecific vessel staining was not
observed in sections that were stained with the pepDBpHER3 (Fig-
ures 6A–6E).
DISCUSSION
In this paper, we introduce a concept for the use of bispecific
molecules in adiagnostic setting todetect PPIs andprotein phos-
phorylation in FFPE tissue. The method, which we refer to as
the dual binder assay, is different from previously described PPI
detection assays in that it relies on a dramatic increase in the
complex stability of the bispecific detection molecule (i.e., the
DB) if its two Fab fragments, which possess only moderate
off-rate kinetics, bind their target epitopes simultaneously. In
contrast, in the previously described assays, two high-affinity an-
tibodies yield a positive signal if they are in close proximity (Fre-
driksson et al., 2002; Shi et al., 2009; So¨derberg et al., 2006).
Further, the DB assay does not require a fluorescence-based
detection system. Highly sensitive colorimetric staining proce-
dures are sufficient to allow the detection of low signal intensities,
which are expected for most PPI and protein phosphorylation
events in FFPE tissue. In our setup, the utilized automated IHC
staining instrument also provides the necessary harsh washing
conditions that are needed to reduce background signals from
weak binding of only one Fab fragment of DBs. In addition, the
DB assay is highly specific in a user-friendly experimental setup
in which a DB is used similarly to a traditional antibody, and it
ensures a highly reproducible assay approach due to the auto-
matic platform setup. In the present study, we have shown the
potential of DBs in IHC by studying the activation of HER3 as a
model system and have demonstrated the highly specific detec-
tion of HER2/HER3 heterodimers and phosphorylated HER3.57–368, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 361
Figure 4. Immunohistochemical Staining of Fixed HER-Expressing HEK293 Cells with DNADBpHER3
(A–C) The DB (3 nM) stained HRG-treated (A), but not untreated (B), cells overexpressing HER2 and HER3. HRG-treated cells that expressed a mutant HER3
variant, HER3(YICDF) lacking the ICD phosphorylation sites (C) were not stained.
(D and E) Neither FabSPEC-oligo 2 + linker (D) nor FabPHOS-oligo 1 + linker (E) were able to stain HRG-treated cells.
See also Figure S4.
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‘‘Dual Binders’’ Boost In Situ Detection SpecificityBy utilizing DNA-based linker technology, we introduced a
highly versatile format to rapidly generate DBs that can easily
be optimized with regard to the binding elements as well
as the linker characteristics, such as length, geometry, and
chemical properties. Other bispecific antibody approaches
have been developed (Byrne et al., 2013; Kontermann, 2012;
Chames and Baty, 2009), some of which also utilize flexible
linker molecules (e.g., DNA, polyethylene glycol [PEG], or pep-
tide linkers) (Kazane et al., 2013; Kim et al., 2012). By exploiting
unnatural amino acids for site-specific conjugation of Fab frag-
ments, Kim et al. generated Fab-(PEG-)linker conjugates that
were chemically linked to form defined bispecific antibodies.
Using the same site-specific conjugation approach Kazane
et al. (2013) generated Fab-oligo conjugates that could be
self-assembled into bispecific (or even multispecific) antibodies.
Both described antibody formats and the DNA-based DBs
share the common principle of producing defined bivalent
molecules by combining two site-specifically labeled Fab
fragments. One major difference from the other methods is
the distinct modular setup of the DNA-based DBs, which are
composed of three individual molecules (Fab-oligo 1, Fab-oligo
2, and a linker) and thus allows easy exchange of linker type
and length for a given pair of DNA-labeled Fab fragments
(Figure 1C).
Thoughmost of the bispecific antibody formats that have been
developed have been designed predominantly for therapeutic362 Chemistry & Biology 21, 357–368, March 20, 2014 ª2014 Elseviepurposes, they in principle could also be used in IHC as an inter-
esting alternative to the DB format. One basic requirement, how-
ever, would be suitable kinetic properties of the respective
binders, because the presented detection approach is not based
on high-affinity epitope binding, but relies on the simultaneous
binding of the two binding arms, which in the case of DBs
possess only moderate off-rate kinetics. This links a positive
detection result strictly to the availability of both targeted epi-
topes (in close proximity) in the specimen, leading to an actual
gain in IHC target specificity.
We generated DBs to target the heterodimer between HER2
and HER3, and we investigated its detection in IHC using MCF-
7 and T47D cells. pepDBHER2/HER3- and
DNADBHER2/HER3-stained
HRG-treated cells. Untreated and pertuzumab-treated cells
werenotdetectedby theDBs.These results indicate that thebiva-
lent DBs specifically detected HER2/HER3 heterodimers, but not
the monomeric receptors. In addition, we demonstrated that a
monovalent single arm of DNADBHER2/HER3, which recognized
only HER2 or only HER3, did not bind to the HRG-treated cells.
Consequently, the DBs bound their targets tightly only if HER2
and HER3 were recognized simultaneously in a heterodimer.
The detection of HER2/HER3 heterodimers was very specific
and without background signals of monomeric HER receptors.
Further, the detection of HER2/HER3 heterodimers in MCF-7
and T47D cells using pepDBHER2/HER3 and
DNADBHER2/HER3 is
in agreement with results reported by other researchers whor Ltd All rights reserved
Figure 5. Immunohistochemical Staining of Fixed T47D Cells with pepDBpHER3
(A and B) pepDBpHER3 (0.2 nM) stained HRG-treated (A) but not untreated (B) T47D cells.
(C–E) Epitope peptides of FabSPEC (C) or FabPHOS (D), but not a random peptide (E), inhibited positive staining of HRG-treated cells.
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‘‘Dual Binders’’ Boost In Situ Detection Specificityutilized VeraTag technology to detect HER2/HER3dimerization in
these cell lines (Mukherjee et al., 2011).
As a second application, the DB technology was used to
detect protein phosphorylation. We considered the technology
to be a promising tool to solve the problem of cross-reactivity
of phosphorylation state-specific antibodies, which had previ-
ously limited the reliability of phosphoprotein detection in IHC.
We developed DBs against HER3 (pY1289) that consisted of a
FabPHOS, an HER3-specific (FabSPEC) Fab fragment, and a flex-
ible linker. DBs with two different linker formats, pepDBpHER3
and DNADBpHER3, were characterized by IHC. Both DB variants
stained only cells that had been treated with HRG (which induces
HER3 phosphorylation), demonstrating the phosphorylation
state specificity of the detection molecule. The staining was
shown to be dependent on cooperative binding of both DB
arms (FabPHOS and FabSPEC) to their epitopes, as the availability
of only one monovalent Fab fragment was not sufficient to
generate positive staining. Competitive epitope peptides con-
taining the recognition sequence of FabPHOS or FabSPEC inhibited
positive staining with pepDBpHER3. By comparing
pepDBpHER3
with the corresponding monoclonal anti-pHER3 IgG, both of
which contained the same phosphorylation state-specific para-
tope of FabPHOS, we demonstrated a substantially higher target
specificity of the DB. On a phosphopeptide array chip, which is
a powerful tool with which to validate the phosphorylation state
specificity of detection molecules, pepDBpHER3 reacted specif-
ically only with a pHER3 peptide, in contrast to the anti-pHER3
IgG monoclonal antibody, which reacted strongly with a numberChemistry & Biology 21, 3of different phosphopeptides. This superior specificity of the
pepDBpHER3 was also evident on FFPE sections derived from a
xenograft study in which the anti-pHER3 IgG monoclonal anti-
body, but not pepDBpHER3, unspecifically stained blood vessels
in IHC. Taken together, these findings confirm a strong gain in
specificity of the DB technology with regard to the detection of
phosphoproteins. Consequently, the DB technology may turn
out to be an efficient platform for the generation of highly specific
binding agents against any given phosphoepitope. For example,
it would be interesting to create a DB targeting phosphorylated
insulin-like growth factor type 1 receptor, as state-of-the-art
commercial IgGs show cross-reactivity to the highly similar
phosphorylated insulin receptor. Future research may show
whether it can also be used to specifically detect various other
kinds of PTMs, such as ubiquitination, sumoylation, acetylation,
methylation, and glycosylation, if a FabPTM and a FabSPEC with
appropriate binding kinetics can be generated.
In the aforementioned examples, we used pepDBs and
DNADBs. It would be very interesting to investigate if changes
in linker length, e.g., by including additional GGGGS motives in
pepDBs or HEG motives in DNADBs, could improve the detection
of targets by optimizing the distance between the two Fab
fragments of a DB for dual target recognition. Further, extended
L-DNA or D-DNA sequencesmight also be suitable linkers to join
two Fab fragments of a DB. The potential to carefully engineer
the flexibility and the length of the linker might be an advantage
over conventional diagnostic proximity-based detection assays
in which the distance between targets is limited to the size of57–368, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 363
Figure 6. Specificity Comparisons between
pepDBpHER3 and an Anti-pHER3 IgG
Both binding molecules contained the identical
phosphospecific paratope of FabPHOS, the DBwith
a second specificity due to FabSPEC.
(A) Histogram summarizing results from antibody
specificity profiling experiments on a phospho-
peptide chip onto which a selection of well-known
phosphoepitopes had been spotted. Relative
signal intensities of the most strongly stained
peptide spots after detection with the pepDBpHER3
(gray bars) or the anti-pHER3 IgG (black bars) were
determined. Results from three independent ex-
periments are shown. Data are represented as
mean ± SD.
(B–E) Immunohistological staining of FFPE H322M
xenograft tissue with anti-pHER3 IgG (B and C) or
pepDBpHER3 (D and E). Identical tissue areas (B and
D: pHER3-positive area of the proliferating rim of
the tumor; C and E: pHER3-negative, blood
vessel-rich tissue area) are shown for both staining
methods. pepDBpHER3 (30 nM) or IgG (7 nM) was
used for the IHC staining. Arrows point to blood
vessels (v) or areas of proliferating tumor cells (t).
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that still allows proximity ligation. Theoretically, the distance of
two epitopes is not restricted by utilizing the DB linker technol-
ogy. Most importantly, the minimal distance is shorter than in a
proximity ligation assay as we use Fab fragments with a flexible
linker of appropriate length instead of full IgGmolecules. Conse-
quently, the DBs might be particularly useful to differentiate
between PPIs and proteins in proximity that do not interact.
Nevertheless, the DB technology is limited in the choice of Fab
fragments. The original antibodies need to be well-character-
ized, and only those Fab fragments with appropriate kinetic
properties may be chosen as binding arms for a DB. Oftentimes
the access to this information is not provided in the case of com-
mercial antibodies and has to be determined before DBs can be
developed.
Of the two linker technologies with which to create bispecific
binders described in the present report, the DNA-based DB
(Figure 1C) seems to be particularly attractive. In a first step,
the binding entities that build up a bispecific binder have to
be site-specifically conjugatedwith two different ssDNA oligonu-
cleotides. Subsequently, a whole library of linker molecules,
consisting of different linkers with regard to length, geometry,
chemical properties, and labeling can be used to build up bispe-
cific binders simply by hybridizing the ssDNA oligonucleotides of
the binding entities to linker molecules containing complemen-364 Chemistry & Biology 21, 357–368, March 20, 2014 ª2014 Elsevier Ltd All rights reservedtary ssDNA sequences at their flanking re-
gions. In addition, many different binding
elements can thus be rapidly combined.
In summary, this modular approach al-
lows the easy generation of a great variety
of bispecific binders and hence facili-
tates the optimization procedure for the
respective application. In addition, it
may also be interesting to investigate
the potential of other emerging bispecificantibody formats in immunohistochemical applications. Among
these formats, bispecific molecules with flexible linkers seem
to be especially attractive, as they are sterically less constrained
than antibodies with Fc regions.
SIGNIFICANCE
In the present study, we show that bispecific molecules are
powerful agents to be used in IHC to detect PPIs and protein
phosphorylation in FFPE tissue with high specificity. There-
fore, DBs provide an excellent alternative to conventional
proximity ligation detection methods for academic and clin-
ical research. As opposed to the existing proximity ligation
methods, the DB detection approach combines excellent
target specificity with the advantages of high reproduc-
ibility, preservation of cell and tissue morphology, and
good clinical applicability.
EXPERIMENTAL PROCEDURES
Plasmids, Protein Expression, and Purification
After determination of the amino acid sequences of the Fab fragments, the cor-
responding cDNA, including sequence stretches encoding fusion tags at the C
terminus, was synthesized (Invitrogen GeneArt Gene Synthesis service) and
cloned into a pUC-based expression vector using BamHI/XbaI restriction
enzyme sites downstream of a cytomegalovirus promoter. Recombinant Fab
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cells and purified using standard methods. For more detailed information,
see Supplemental Information.
Antibody Development
Mice were immunized with human HER3(1,242–1,267)[KLH-MP-Cys-UZU-
1243]amide, human HER3(1,093–1,113)[KLH-MP-Cys-UZU-1243]amide, or
human HER2(1,223–1,236)[KLH-MP-Cys-UZU]amide. Spleen cells of immu-
nized mice were fused with myeloma cells as described previously (Galfre`
and Milstein, 1981). Immunization details are provided in the Supplemental In-
formation. The antibody-containing supernatants of primary myeloma cultures
were tested for antigen specificity by ELISA using streptavidin-coated 384-
well plates that were incubated with the respective biotinylated target pep-
tides. The positive primary cultures were cloned in 96-well cell culture plates
by means of a fluorescence-activated cell sorter. After subsequent growth in
a 24-well plate, a 6-well plate, and a T75 flask (Corning) in HyClone medium
(Thermo Scientific) with Nutridoma supplements (Roche), the hybridoma cells
expressing the desired antibodies were cultured in a CELLine bioreactor
(INTEGRA Biosciences) according to the manufacturer’s instructions.
The anti-pHER3 rabbit monoclonal antibody recognizing human
HER3(1,283–1,295; pY1289) was developed by EpitomicsTM using hybridoma
technology. Cultivation of the respective hybridoma clone was performed as
described previously for mouse hybridoma cells.
Antibody Sequencing
Hybridoma cells that express the desired antibody were counted, and 1.2 3
106 cells were centrifuged for 7 min at 1,200 rpm. The supernatant was dis-
carded, and the cell pellet was washed with PBS and frozen at 80C. RNA
was isolated using an RNeasy Mini Kit (QIAGEN). Next, 1.5 mg of RNA was
used for AccuScript High Fidelity 1st strand cDNA synthesis (Agilent Technol-
ogies). Subsequently, the variable (V) region coding sequences of the anti-
bodies were amplified as described previously (Doenecke et al., 1997) using
the 50/30-RACE Kit, 2nd Generation (Roche Applied Science).
Oligonucleotide Synthesis
The following sequences of oligonucleotide derivatives were synthesized for
Fab labeling/conjugation or as ssDNA linkers: (Sequence I) 50-fluorescein-
AGT CTA TTA ATG CTT CTG C-(Spacer C3)-30-amino linker; (Sequence II)
amino linker (Spacer C3)3-AG TTC TAT CGT CGT CCA-fluorescein-30;
(Sequence III) 50-G CAG AAG CAT TAA TAG ACT C18 amino modifier C6 dT
C18 TGG ACG ACG ATA GAA CT-30; (Sequence IV) 50-fluorescein-AGT CTA
TTA ATG CTT CTG C-(Spacer C3)3-amino linker-(Gly)4-30; (Sequence V) 50-
(Gly)4-amino linker-(Spacer C3)3-AG TTC TAT CGT CGT CCA-fluorescein-
30; (Sequence VI) 50-fluorescein-AGT CTA TTA ATG CTT CTG C-(Spacer C3)
3-amino linker-BG-GLA-30; (Sequence VII) 50-BG-GLA-amino linker-(Spacer
C3)3-AG TTC TAT CGT CGT CCA-fluorescein-30; and (Sequence VIII) 50-G
CAG AAG CAT TAA TAG ACT C18 dig-amino modifier C6 dT C18 TGG ACG
ACG ATA GAA CT-30.
Fluorescein-labeled and/or amino-modified oligonucleotide Sequences (I),
(II) and (III) were synthesized in an automated DNA synthesizer (model 394;
Applied Biosystems) at 10 mM employing standard phosphoramidites, as
well as commercial amidites and supports, according to the standard proce-
dure for solid-phase synthesis of oligonucleotides previously described in the
literature (Seela and Budow, 2007). We used 30-Amino Modifier TFA Amino
C-6 lcaa CPG 500 A˚ (ChemGenes N-1004-05) for 30-amino modifications,
50-Amino-Modifier C6 (Glen Research 10-1906) for 50 amino modifications
and amino modifier C6 dT (Glen Research 10-0139) for internal amino mod-
ifications. Fluorescein labeling was performed using 50-fluorescein phosphor-
amidite (Glen Research 10-5901) for 50 labeling and LightCycler Fluorescein
CPG 500 A˚ (Roche Applied Science 03138178001) for 30 labeling. HEG
spacers were introduced using Spacer Phosphoramidite 18 (Glen Research
10-1918), and C3 spacers were introduced using Spacer Phosphoramidite
C3 (Glen Research 10-1913). After cleavage from the solid support, the
oligonucleotides were deprotected in 25% aqueous ammonia solution for
12–16 hr at 60C. After cleavage from the solid support, the oligonucleotides
were deprotected in 25% aqueous ammonia solution for 12–16 hr at 60C.
The oligonucleotides were purified by reversed-phase high-performance
liquid chromatography (RP-HPLC). For the synthesis of Sequences (IV) andChemistry & Biology 21, 3(V), Sequences (I) and (II) were labeled with fluorenylmethyl chloroformate
Gly4 N-hydroxysuccinimide (Fmoc Gly4 NHS) ester. For the synthesis of
Fmoc Gly4 NHS, 5.3 mg of 0.047 mM N-hydroxysuccinimide (Merck) were
added to a solution of 20 mg of 0.043 mM Fmoc Gly4 (Bachem) in 0.5 ml
of dry N,N-dimethylformamide (DMF) [5.3 mg (0.047 mM)]. A solution of
10.7 mg of N,N0-dicyclohexylcarbodiimide (Fluka) in 0.5 ml dry DMF was
added in a dropwise manner. The solution was stirred under argon overnight
at room temperature. Ethylacetate (10 ml) was added and filtrated. The
filtrate was evaporated to dryness by using a rotary evaporator. The residue
was again dissolved in ethylacetate and filtrated, and the filtrate was evapo-
rated under reduced pressure to dryness by using a rotary evaporator. The
residue was dried in a high vacuum. The yield of raw material was 25 mg
(used for labeling without further purification). For the labeling, a solution of
the crude Fmoc Gly4 NHS ester (25 mg) dissolved in 1 ml of DMF was added
to a solution of the amino-modified oligonucleotide Sequence (I) or (II)
(0.02 mM) in 1 ml of 0.1 M borate buffer at pH 8.5. The mixture was stirred
at room temperature for 24 hr. The mixture was evaporated to dryness by
using a rotary evaporator. The crude oligonucleotide was purified by using
standard RP-HPLC methods, and the Fmoc group was removed by dissolv-
ing the Fmoc Gly4 oligonucleotide in 5 ml of water, to which 600 ml of piper-
idine was added. After 30 min of stirring at room temperature, the solvents
were removed by using a rotary evaporator. The remainder was dissolved
in water and evaporated to dryness by using a rotary evaporator. Desalting
was performed by using a Vivaspin MWCO 5,000 Da centrifugal concentrator
column (Sartorius Stedim Biotech). For the synthesis of oligonucleotide
Sequences (VI) and (VII), Sequences (I) and (II) were labeled with BG-GLA-
NHS ester (NEB S9151S; New England Biolabs) as described previously
(Meyer and Niemeyer, 2011). For the linker molecule Sequence (VIII),
Sequence (III) was labeled with digoxigenin NHS ester (digoxigenin-3-O-
methylcarbonyl-x-aminocaproic acid N-hydroxysuccinimide ester; Roche
Applied Science 11333054001) as described in the manufacturer’s instruc-
tions for use.
Preparation of Fab-Oligonucleotide Conjugates
The synthesis of site-specific and covalently joined Fab-oligonucleotide con-
jugates by enzymatic/sortase-mediated transpeptidation has been described
previously (Pritz et al., 2007). Briefly, 50 mM Fab fragment containing the sor-
tase recognition sequence LPETG at the C-terminal end of the Fab heavy
chain were incubated with 200 mM oligonucleotide [either oligonucleotide
Sequence (IV) or (V); see Oligonucleotide Synthesis] and 10 mM recombinant
sortase in a buffer of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM CaCl2, at 37
C
overnight. Next, the labeling reaction was diluted 103 in 20 mM Tris, pH 8.0,
and applied to a Resource Q ion exchange column (GE Healthcare) that was
equilibrated in 20 mM Tris at pH 8.0. The oligonucleotide and the Fab-oligo-
nucleotide conjugate were eluted with a high salt gradient of 20 mM Tris, pH
8.0, and 1 M NaCl. The elution was monitored following absorbance at
495 nm, which allowed us to detect the fluorescein labeling of the oligonucle-
otide. The Fab-oligonucleotide conjugate was further purified by SEC using a
HiLoad 16/60 Superdex 200 PG column (GE Healthcare) and 20 mM Tris, pH
8.0, and 200 mM NaCl as equilibration and running buffers. The purity of the
final Fab-oligonucleotide conjugate was analyzed by gel filtration and SDS-
PAGE. Only Fab-oligonucleotide conjugate preparations >90% purity were
used for the assembly of DBs.
Ligation of oligonucleotides [Sequence (VI) or (VII); see Oligonucleotide Syn-
thesis] with Fab fragments containing the SNAP-Tag instead of the sortase
recognition tag at the C-terminal end of the Fab heavy chain was performed
in a buffer of 50 mM Tris, pH 7.5, and 150 mM NaCl with a molar ratio of 4:1
oligonucleotide/Fab fragment. The reaction was performed at 4C overnight.
The Fab-oligonucleotide conjugate was separated from unreacted oligonucle-
otide by utilizing a gel filtration preparation on a HiLoad 16/60 Superdex
200 PG column using 20 mM Tris, pH 8.0, and 200 mM NaCl as equilibration
and running buffers. The purity of the final product was analyzed by SEC
and SDS-PAGE. Only Fab-oligonucleotide conjugate preparations >90%
purity were used for the assembly of DBs.
Analytical Size Exclusion Chromatography
Analytical SEC was performed using a GE Healthcare Life Sciences Superdex
200 10/300 GL SEC gel filtration column with a flow rate of 0.5 ml/min.57–368, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 365
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buffer, and an 50 pM sample was injected in each run. The retention volume
was monitored by a change in absorbance at 280 nm (aromatic absorbance)
and 495 nm (fluorescein absorbance).
Peptide Synthesis
Solid-phase synthesis of the peptide reagents from the HER family was per-
formed employing the Fmoc/tert-butyl strategy. The phosphopeptide chip
array used to evaluate phosphoepitope binding specificity consisted of a
library of 277 immobilized, phosphorylated (pY) peptide fragments (length:
15 aa) derived from 39 human proteins. For preparation of the peptide array,
the CelluSpotsTM technology was employed. In this approach, peptides are
synthesized with an automated synthesizer (intavis MultiPep RS) on modified
cellulose disks, which are dissolved after synthesis. The solutions of individual
peptides covalently linked to macromolecular cellulose are then spotted onto
coated microscope slides. For more detailed information, see Supplemental
Experimental Procedures.
Surface Plasmon Resonance Measurements
Kinetic screening for the selection of antibodies with suitable off-rate kinetics
was performed on a Biacore A100 instrument from primary hybridoma culture
supernatants essentially as described elsewhere (Schra¨ml and Biehl, 2012).
Subsequent detailed characterization of selected antibodies was performed
on a Biacore T200 instrument mounted with a Biacore CM-5 series S sensor.
The instrument buffer was HBS-EP (10 mM 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.05% P20 (w/v)).
Polyclonal rabbit anti-mouse Fc-g-specific antibody (30 mg/ml; GE Healthcare
Life Sciences) in 10mMsodium acetate buffer (pH 4.5) was immobilized in flow
cells 1, 2, 3 and 4 at 12,700 RU by using NHS/3-(ethyliminomethyleneamino)-
N,N-dimethylpropan-1-amine chemistry as recommended by the manufac-
turer. Flow cell 1 served as a reference. The clone culture supernatants from
recloned hybridoma containing the monoclonal antibodies were injected
for 5 min at 5 ml/min. The peptides HER3_human(1,093–1,113)-bi-PEG-
amide (3 kDa) or HER2_human(1,223–1,236)-bi-PEG-amide (2 kDa), and
HER3_human(1,242–1,267)-bi-PEG-amide (3 kDa) were diluted in instrument
buffer supplemented with 1 mg/ml carboxymethyldextran (Sigma-Aldrich)
and were injected at concentration series of 4 nM, 11 nM, 33 nM, 90 nM,
and 270 nM at 30 ml/min for 5 min of contact time. The dissociation phase
was monitored for 5 min. The capture system was regenerated by 10 mM
glycine HCl solution (pH 1.7) for 3 min at a flow rate of 10 ml/min. Kinetic
data were calculated according to a Langmuir model using evaluation software
according to the manufacturer’s instructions.
Cell Culture, Cell Fixation, and Cell Embedding
MCF-7, T47D, and HEK293 cells were cultured as monolayers using RPMI
1640 (GIBCO), 2 mM L-glutamine (GIBCO), 10% fetal calf serum, and grown
to optical confluence in a T175-cm2 flask. HEK293 cells were transiently
transfected with pRK5 expression plasmids encoding HER1, HER2, HER3,
HER3(YICDF), and HER4 complexed by FuGENE 6 transfection reagent (Roche
Applied Science) according to the manufacturer’s instructions. HER3(YICDF) is
a mutated version of HER3 in which all tyrosines of the ICD are replaced by
phenylalanines and consequently lacks all ICD tyrosine phosphorylation sites.
Confluent MCF-7 and T47D cells were starved in RPMI 1640 medium and
2 mM L-glutamine for approximately 18 hr. The cells were then stimulated
with 20 nM neuregulin 1 (NRG1)-b1 (Peprotech) for 15 min at 37C. As a
negative control, cells were left without stimulation for 15 min at 37C in
RPMI 1640 medium and 2 mM L-glutamine. For inhibition experiments, sam-
ples were incubated with 160 nM pertuzumab for 1 hr after starvation and
before stimulation with 20 nM NRG1-b1 for 15 min in the presence of
160 nM pertuzumab. Transfected HEK293 and T47D cells were detached
from the flask using accutase and centrifuged for 5 min at 1,000 rpm and
4C. The cell pellets were resuspended in 100 ml of 10% formaldehyde and
transferred onto a 96-well, flat-bottomed plate (Corning). Next, 100 ml of
0.5% agarose/PBS at 60C were added. After being mixed, the samples
were incubated at 4C for 15 min. The agarose gel blocks containing the cell
pellets were incubated in 10% formaldehyde overnight, washed for 1 hr under
running water, dehydrated in ethanol and xylol, and embedded in paraffin.
MCF-7 cells were fixed with formalin and embedded in paraffin as described366 Chemistry & Biology 21, 357–368, March 20, 2014 ª2014 Elseviepreviously (Fazio-Eli et al., 2011). All cell blocks were produced at least twice
to ensure the reproducibility of the results.
Immunohistochemistry
All immunohistochemical staining was performed with 3-mm slides of FFPE
cellular or tissuematerial on Superfrost Plusmicroscope slides (Thermo Scien-
tific). Themanual pHER3 IHC to validate HER3 activation after HRG stimulation
was performed after hydrating microscope slides in baths of xylol, 100%
ethanol, 90% ethanol, 80% ethanol, 70% ethanol, H2O and PBS. Antigen
retrieval was performed for 10 min at 97C in target retrieval solution (Dako)
following a 20-min cooling phase to 60C. The slides were incubated at
4C overnight with 7 ng/ml primary pHER3 antibody (4791; Cell Signaling
Technology) in antibody diluent (Dako). The Lab Vision UltraVision LP Large
Volume Detection System (Thermo Scientific) and DAB+ (Dako) were used
as 3,30-diaminobenzidine (DAB) detection systems. Counterstaining was
performed using Mayer’s hematoxylin solution for 5 min.
Anti-HER2 and anti-HER3 antibody containing hybridoma supernatants
were diluted to 0.1–10 mg/ml in antibody diluent (Ventana Medical Systems).
The staining was performed on the Ventana Medical Systems BenchMark
XT automated IHC platform using the ultraView Universal DAB Detection Kit
(Ventana Medical Systems), Cell Conditioning 1 (CC1) standard antigen
retrieval, an antibody incubation time of 32 min at 37C, ultraWash procedure,
counterstaining with Hematoxylin II for 4 min and bluing reagent for 8 min.
For detection of HER2/HER3 heterodimers and pHER3 with the Ventana
Medical Systems BenchMark XT autostainer, the microscope slides were
deparaffinized and treated with CC1 buffer for 32 min or 92 min, respectively,
for antigen retrieval. DBs were diluted with antibody diluent (Ventana Medical
Systems), and 100 ml was manually applied to the slides and incubated for
16 min at 37C. The anti-HA-Tag antibody C29F4 (Cell Signaling Technology)
was diluted 1:400 in VentanaMedical Systems antibody diluent, then used as a
bridging antibody to detect pepDB. A monoclonal anti-digoxigenin antibody
(Roche) was diluted 1:100 to detect DNADB. For competition experiments,
the DB was applied as a mixture with 25 mg/ml HER3_human(1,093–
1,113)-bi-PEG-amide, HER2_human(1,223–1,236)-bi-PEG-amide, HER3_
human(1,242–1,267)-bi-PEG-amide or HER3_human(1,283–1,295; pY1289)-
bi-PEG-amide. As a postfixative, 100 ml of the bridging antibody was applied
and incubated for 24 min. Counterstaining was performed using Hematoxylin
II (Ventana Medical Systems) for 4 min and bluing reagent (Ventana Medical
Systems) for 4 min. The same protocol without bridging antibody was used
in IHC experiments with the anti-pHER3 IgG that contained the FabPHOS of
pepDBpHER3. In the case of pHER3 detection in FFPE tissue sections, an addi-
tional amplification step was added by using the OptiView Amplification Kit
(Ventana Medical Systems) and 4-min incubation steps using OptiView Ampli-
fication H2O2 and OptiView Amplification Multimer.
Antibody Specificity Profiling on a Phosphopeptide Chip
Antibody specificity profiling experiments were performed on a Ventana
Medical Systems BenchMark XT automated IHC platform using the Ventana
Medical Systems OptiView DAB Detection Kit. Anti-phospho-HER3 antibody
(1 nM) or 0.5 nM PepDBpHER3 were applied manually to the phosphoepitope
chip and incubated for 16 min at 37C. For detection of PepDBpHER3, the
anti-HA-Tag antibody C29F4 (Cell Signaling Technology) was diluted 1:400
and used as a bridging antibody. The most strongly stained peptide spots
on the chip [HER3(1,243–1,295; pY1289, VEGFR3(1,330–1,344; pY1337],
FGFR1(759–773; pY766), FGFR2(762–776; pY769), FGFR3(753–767; pY760),
and FGFR4(747–761; pY754)] were quantified using the Molecular Imager
ChemiDoc XRS System (Bio-Rad Laboratories) and the volume analysis tool
of the Image Lab 4.0.1 software. Adjusted volume intensities (i.e., volume
intensities after background subtraction) were determined for each of the
selected spots. Relative signal intensities reflected the ratio of a measured
adjusted volume intensity divided by the measured adjusted volume intensity
for the pHER3 peptide spot.
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